Thrombotic Thrombocytopenic Purpura - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Thrombotic Thrombocytopenic Purpura – Comprehensive Guide

Thrombotic Thrombocytopenic Purpura (TTP)

Overview

Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life‑threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the body's arterioles and capillaries. These clots consume platelets, leading to a low platelet count (thrombocytopenia) and cause organ damage by restricting blood flow.

  • Incidence: Approximately 4–6 cases per million people each year in the United States and Europe.1
  • Age & Gender: Classic (immune) TTP most commonly affects adults 30–50 years old, with a female predominance (about 2‑to‑1). Congenital (hereditary) TTP can present at any age, often in childhood.
  • Geography: No major regional differences have been noted, though reporting may be higher in regions with robust hemato‑oncology networks.

Symptoms

TTP typically presents with a rapid onset of symptoms affecting multiple organ systems. The classic “pentad” (five clinical features) is still taught, but many patients present with only a few of these.

Hematologic Symptoms

  • Thrombocytopenia: Easy bruising, petechiae (tiny red spots), or spontaneous bleeding (e.g., gum or nosebleeds).
  • Microangiopathic hemolytic anemia (MAHA): Fatigue, pallor, shortness of breath, and dark urine due to red‑cell fragmentation.

Neurologic Symptoms

  • Headache, confusion, or altered mental status.
  • Seizures, focal weakness, or visual disturbances.
  • Rarely, coma or stroke‑like deficits.

Renal Symptoms

  • Acute kidney injury – decreased urine output, flank pain, or hematuria.
  • May progress to oliguria or renal failure if untreated.

Gastrointestinal Symptoms

  • Nausea, vomiting, abdominal pain, or diarrhea.
  • Occasional gastrointestinal bleeding.

Other Signs

  • Fever (often low grade).
  • Cardiac involvement – chest pain or heart failure due to microvascular thrombosis.

Because the presentation can be heterogeneous, a high index of suspicion is essential, especially when thrombocytopenia co‑exists with hemolytic anemia.

Causes and Risk Factors

Two major pathways lead to TTP:

1. Immune‑mediated (Acquired) TTP

  • Autoantibodies against ADAMTS13: The enzyme ADAMTS13 normally cleaves ultra‑large von Willebrand factor (vWF) multimers. Inhibitory antibodies reduce its activity (<10 % of normal), allowing large vWF strings to promote platelet clumping.
  • Triggers:
    • Pregnancy (especially postpartum) – accounts for ~5‑10 % of cases.2
    • Medications – quinine, cyclosporine, ticlopidine, clopidogrel, certain antiplatelet agents, and some chemotherapy drugs.
    • Infections – HIV, influenza, COVID‑19, and bacterial sepsis have been reported as precipitants.
    • Autoimmune diseases – systemic lupus erythematosus (SLE), rheumatoid arthritis.

2. Congenital (Hereditary) TTP

  • Mutations in the ADAMTS13 gene leading to lifelong deficiency.
  • Often presents in infancy or early childhood with episodic thrombocytopenia and hemolysis, triggered by infections, surgery, or pregnancy.

Risk Factors

  • Female sex (immune TTP).
  • Recent pregnancy or childbirth.
  • History of prior TTP episode – relapse risk up to 30‑40 % without prophylaxis.3
  • Underlying autoimmune disease.
  • Certain drugs (see above).

Diagnosis

Prompt diagnosis is crucial; mortality exceeds 90 % if untreated, but falls below 10 % with early plasma exchange.

Initial Laboratory Evaluation

  • Complete blood count (CBC): Platelet count typically <100 × 10⁹/L; evidence of anemia.
  • Peripheral blood smear: Schistocytes (fragmented RBCs) – a hallmark of MAHA.
  • LDH (lactate dehydrogenase): Markedly elevated due to cell lysis.
  • Haptoglobin: Low or undetectable.
  • Creatinine and BUN: Assess renal involvement.
  • Coagulation studies (PT, aPTT, fibrinogen): Usually normal, helping distinguish TTP from disseminated intravascular coagulation (DIC).

Specific Tests for ADAMTS13

  • Activity assay: <10 % activity strongly suggests TTP.
  • Inhibitor assay: Detects auto‑antibodies in acquired TTP.
  • Results can take 1‑3 days; treatment should not be delayed while awaiting them.

Scoring Systems

The PLASMIC score (Platelets, hemolysis, no active cancer, no solid organ transplant, MCV, INR, Creatinine) predicts likelihood of severe ADAMTS13 deficiency and guides early therapy.4

Imaging

  • CT or MRI of brain if neurologic deficits are present.
  • Renal ultrasound for unexplained kidney injury.

Treatment Options

Therapy combines rapid removal of pathogenic antibodies, replenishment of ADAMTS13, and supportive care.

1. Therapeutic Plasma Exchange (TPE)

  • First‑line, cornerstone of treatment.
  • Typically 1–1.5 plasma volumes exchanged daily until platelet count >150 × 10⁹/L and LDH normalizes (usually 5‑7 days).
  • Replaces deficient ADAMTS13 and removes inhibitory antibodies.

2. Immunosuppression

  • Corticosteroids: Methylprednisolone 1 mg/kg/day IV or oral prednisone.
  • Rituximab: Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks. Reduces relapse rates from ~30 % to <10 % in many series.5
  • Caplacizumab: Nanobody that blocks vWF‑platelet interaction. FDA‑approved (2020) for acquired TTP; accelerates platelet recovery and shortens TPE duration.6
  • Other agents (cyclophosphamide, mycophenolate) are reserved for refractory disease.

3. Supportive Care

  • Transfusion of red cells for symptomatic anemia (avoid platelet transfusion unless life‑threatening bleeding).
  • Renal replacement therapy if acute kidney injury progresses.
  • Antibiotics for documented infection; prophylactic antimicrobials are not routinely recommended.

4. Management of Congenital TTP

  • Regular prophylactic plasma infusions (10–15 mL/kg) every 2‑3 weeks.
  • Recombinant ADAMTS13 (e.g., rADAMTS13) is in late‑stage clinical trials and may become standard in the near future.

Living with Thrombotic Thrombocytopenic Purpura

Even after remission, ongoing vigilance is essential.

Follow‑up Schedule

  • First month: weekly CBC and LDH.
  • Months 2‑6: bi‑weekly to monthly labs.
  • Then every 3‑6 months for life, or sooner if symptoms recur.

Medication Adherence

  • Complete the full rituximab course even if you feel better.
  • Caplacizumab is typically continued for 30 days after the last plasma exchange.

Lifestyle Recommendations

  • Hydration: Maintain adequate fluid intake to help kidney function.
  • Avoid high‑risk drugs: Quinine, certain antiplatelets, and new herbal supplements should be discussed with your hematologist.
  • Vaccinations: Annual flu shot and COVID‑19 vaccine (non‑live formulations) are safe and reduce infection‑triggered relapses.
  • Pregnancy planning: Women with a history of TTP should be cared for by a high‑risk obstetric team; prophylactic plasma exchange may be needed during pregnancy.

Psychosocial Support

Living with a rare, potentially recurrent disease can be stressful. Consider:

  • Joining patient advocacy groups (e.g., TTP Foundation).
  • Counseling or support groups.
  • Use of a medical alert bracelet indicating “TTP – requires plasma exchange if bleeding.”

Prevention

Because many cases are immune‑mediated, true primary prevention is limited, but steps can lower trigger exposure.

  • Inform all healthcare providers of your TTP history before any surgery or new medication.
  • Screen and treat infections promptly.
  • During pregnancy, work with a multidisciplinary team for close monitoring.
  • For hereditary TTP, maintain scheduled plasma infusions to keep ADAMTS13 activity above the protective threshold.

Complications

If diagnosis or treatment is delayed, microvascular thrombosis can cause irreversible organ damage.

  • Neurologic: Stroke, seizures, permanent cognitive deficits.
  • Renal: Acute kidney injury progressing to chronic renal failure or dialysis dependence.
  • Cardiac: Myocardial infarction due to coronary microthrombi.
  • Hematologic: Severe bleeding or uncontrolled hemolysis requiring transfusion.
  • Relapse: Up to 30‑40 % of untreated patients experience recurrent episodes, each carrying the same mortality risk.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you develop any of the following:
  • Sudden, severe headache or confusion.
  • Rapidly worsening bruising, petechiae, or unexplained bleeding.
  • Dark (cola‑colored) urine or sudden drop in urine output.
  • Chest pain, shortness of breath, or palpitations.
  • New weakness, numbness, difficulty speaking, or vision loss.
  • Fever >38 °C (100.4 °F) with any of the above signs.
Prompt treatment can be lifesaving.

References:

  1. CDC. “Thrombotic Thrombocytopenic Purpura.” https://www.cdc.gov. Accessed May 2026.
  2. Mayo Clinic. “Thrombotic Thrombocytopenic Purpura (TTP).” https://www.mayoclinic.org. Accessed May 2026.
  3. Cleveland Clinic. “Thrombotic Thrombocytopenic Purpura.” https://my.clevelandclinic.org. Accessed May 2026.
  4. Fever, C. et al. “The PLASMIC Score for Predicting Severe ADAMTS13 Deficiency in Thrombotic Thrombocytopenic Purpura.” *Blood*, 2020.
  5. Joly, B. et al. “Rituximab for Acquired TTP: Long‑Term Outcomes.” *The New England Journal of Medicine*, 2021.
  6. International Society on Thrombosis and Haemostasis. “Caplacizumab in Acquired TTP: Clinical Data.” *J Thromb Haemost*, 2022.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References